USPTO 2015–2025 USPTO PatentsView US Corporation

Janssen Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 769 granted patents across 46 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

769

Total patents granted

CPC technology areas

17.3

Avg claims per patent

+4%

5-year filing velocity

The verdict

Janssen holds 769 US patents across 46 technology areas, rank #584 of 50,000 tracked assignees.

#584
of 50,000 US assignees by volume: Top 2%
by Innovation Score (63.4/100): 17.3
avg claims per patent: +4%
filing velocity, last 5 yrs

Portfolio overview

Janssen Pharmaceuticals, Inc. has been granted 769 US utility patents between 2015 and 2025, placing Janssen Pharmaceuticals, Inc. at rank #584 across all assignees tracked by PlainPatent. This portfolio spans 46 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Janssen Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Janssen sits between Hitachi Construction Machinery Co., Ltd. (771 patents, rank #580) and Mediatek Singapore Pte. Ltd. (761 patents, rank #588) - the closest US assignees by grant volume. The composite Innovation Score of 63.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 392 grants, compared with 377 in the 2015–2019 window, a +4% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Janssen Pharmaceuticals, Inc.'s 17.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 46 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Janssen Pharmaceuticals, Inc. against peers pursuing similar technology classes.

Hitachi Construct…

771
Novozymes A/S

770
Axis AB

769
Globalfoundries S…

769
Medtronic Minimed

769
Janssen Pharmaceu… ◀

769
Cochlear

768
Mellanox

766
Mediatek Singapor…

761

What this shows Janssen holds 769 patents at rank #584, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #584 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Janssen's primary technology class.

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

63 Top 2% higher than 98% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Janssen Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	95	12.4%
2016	72	9.4%
2017	76	9.9%
2018	71	9.2%
2019	63	8.2%
2020	78	10.1%
2021	74	9.6%
2022	65	8.5%
2023	67	8.7%
2024	65	8.5%
2025	43	5.6%

Which technologies does Janssen Pharmaceuticals, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 592

C07D - HETEROCYCLIC COMPOUNDS 492

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 384

C07K - PEPTIDES 105

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 69

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 60

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 54

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 34

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 32

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 26

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 24

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 22

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 21

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 13

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 10

Top 15 of 46 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#584

Across all tracked assignees

Innovation Score

63.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Janssen Pharmaceuticals, Inc. hold?

Janssen Pharmaceuticals, Inc. holds 769 US granted patents filed between 2015 and 2025, spanning 46 technology areas.

What is Janssen Pharmaceuticals, Inc.'s Innovation Score?

Janssen Pharmaceuticals, Inc. has an Innovation Score of 63.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Janssen Pharmaceuticals, Inc. focus on?

Janssen Pharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 592 patents. The company has filed patents in 46 CPC subclasses total.

Is Janssen Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?

Janssen Pharmaceuticals, Inc.'s recent filing velocity is +4% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Janssen Pharmaceuticals, Inc.'s patents?

Janssen Pharmaceuticals, Inc.'s patents average 17.3 claims each. This falls within the standard range, providing solid legal coverage.

How is the Janssen Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Janssen's 769 grants land it in the top 2% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Janssen ranks #584 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.